ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Olaparib is on this study

  • The record lists it as a treatment, written “olaparib+cediranib combination therapy”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 3, 2026, 2:43 AM UTC“With cediranib or durvalumab in umbrella arms”
  • The role rule says the same.
  • So Olaparib's page lists this study under “Testing it”.
5 links1 made here, not in the record8 judgments2 judges (the rules as one: Rule based)2 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT03699449An uMbrella Study ofBIomarker-driven TargetedTherapy In Patients WithPlatinum-resistantRecurrent OvariaNCancer(AMBITION)Yonsei UniversityPhase 2 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedNov 18 · ClinicalTrials.gov record · Version of 2026-11-18Version of 2026-11-18CONDITIONSOvarian NeoplasmsNo longer in the registry's filing›As of now · Rule based · Main conditionMain conditionDRUGSOlaparibEntry “olaparib+cediranib combination…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCediranibEntry “olaparib+cediranib combination…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDurvalumabEntry “durvalumab + olaparib combinat…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTremelimumabMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Nov 18 · changes seen, not judgments
Nov 3OlaparibClaude Opus 5.5TestedCurrent
Nov 3CediranibClaude Opus 5.5TestedCurrent
Nov 3DurvalumabClaude Opus 5.5TestedCurrent
Nov 3Tremelimumabmade hereClaude Opus 5.5TestedCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 18OlaparibRule based · role ruleTestedAgrees
Nov 18CediranibRule based · role ruleTestedAgrees
Nov 18DurvalumabRule based · role ruleTestedAgrees
As of nowOvarian NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.